September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
June 2014 in “Reactions Weekly” October 2023 in “Journal of cystic fibrosis” January 2014 in “Reactions Weekly” April 2026 in “Reactions Weekly” December 2024 in “Reactions Weekly” November 2014 in “Reactions Weekly” July 2014 in “Reactions Weekly” August 2013 in “Reactions Weekly” January 2013 in “Reactions Weekly” December 2012 in “Reactions Weekly” August 2012 in “Reactions Weekly” March 2012 in “Reactions Weekly” August 2011 in “Reactions Weekly” May 2011 in “Reactions Weekly” April 2011 in “Reactions Weekly” March 2011 in “Reactions Weekly” April 2010 in “Reactions Weekly” September 2009 in “Reactions Weekly” August 2009 in “Reactions Weekly” February 2009 in “Reactions Weekly” October 2008 in “Reactions Weekly” October 2008 in “Reactions Weekly” February 2008 in “Reactions Weekly” November 2007 in “Reactions Weekly” January 2004 in “Reactions Weekly”